Scientists turn protein-making errors in cancer cells into a targeted kill switch
· Medical Xpressby Sanjukta Mondal, Medical Xpress
Sanjukta Mondal
Author
Meet our staff & contributors
Learn about our editorial standards
edited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add to Preferred Sources
Like every other cell in the human body, cancer cells also produce their own share of proteins for survival. During this production process, cells often encounter a glitch called ribosomal frameshifting. This exceptionally rare event occurs roughly once in every 100,000 translation events, when the ribosome, while reading genetic instructions to make a protein, shifts its reading position. A recent Nature study investigated whether this protein-building glitch in cancer cells can be turned into a targeted cancer therapy.
Ribosomes read mRNA in groups of three genetic letters, known as codons. To find out where this reading process goes wrong, the researchers developed high-throughput dual-luciferase reporter libraries containing randomized genetic sequences. This allowed them to systematically track instances where ribosomes slipped out of their usual reading frame.
The ribosome profiler pinpointed specific codon pairs, such as AGAACG, that frequently trigger ribosomes to slip backward by one letter (a −1 frameshift) in cancer cells. Noncancerous cells, however, read these sequences normally.
The researchers turned this property of cancer cells into an advantage by building a synthetic therapy circuit called FAST (frameshifting-activated synthetic therapeutic circuit), which uses the ribosome's backward slip as a trigger to activate a protein that can punch holes in the cell membrane, setting off an inflammatory form of cell death known as pyroptosis.
Do cancer cells glitch under normal conditions?
Scientists have studied this process extensively in viruses, where it helps them produce a wider range of proteins from their genetic material. In mammals, however, frameshifting is considered extremely rare under normal conditions.
Previous research has shown that stress conditions such as nutrient shortages can trigger frameshifting in human cancer cells. Not much was known about whether similar shifting can occur in cancer cells under normal growth conditions.
The researchers wanted to find out whether this tendency could be exploited to solve a persistent problem in cancer treatment: how to make toxic therapies switch on in tumor cells while leaving healthy tissues unharmed.
They set up a large-scale screening model to identify and verify frameshifting-prone sequences in a variety of human and mouse cancer cell lines, such as melanoma, liver, colorectal and ovarian cancer. The researchers developed a specialized computational pipeline to track ribosomes as they read mRNA transcripts and pinpoint pairs of codons where they struggled to maintain the normal reading frame. They also built in guardrails to ensure that the signals they detected came from actual ribosomal frameshifting, rather than other ribosome-related processes.
Their analysis revealed that cancer cells naturally undergo −1 ribosomal frameshifting, in which ribosomes slip backward by one genetic letter at specific codon pairs, such as AGAACG and ACGAGA. This often produces detectable peptides or proteins, such as gasdermin D (GSDMD-N), from the altered genetic instructions.
The researchers traced this slippage to elevated phosphorylation of ribosomal protein S6 (pRPS6), which pushes paused ribosomes into an alternative reading frame. This phosphorylation is driven by the mTOR and MAPK growth signaling pathways, which are often overactive in cancer cells.
Harnessing the error for good
The researchers designed FAST to exploit the frameshifting tendency of cancer cells. They placed a fragment of GSDMD-N responsible for forming pores in the −1 reading frame, just behind the codon sequence that triggers ribosomes to slip backward.
When cancer cells underwent the shift, they produced a protein fragment that punched holes in their membranes, causing the cells to burst and die through an inflammatory process called pyroptosis. Normal cells, which read the sequence in the usual way, remain unharmed.
When delivered intravenously into a mouse model, FAST triggered substantial tumor regression in colorectal cancer (MC38) and spontaneous pancreatic cancer (KPC mice). It also curbed the spread of cancer to the liver and lungs. FAST also boosted immune activity within tumors and proved more effective when combined with immune checkpoint inhibitors. Tests in mice found no inflammation or organ toxicity in healthy tissues of major organs.
These findings offer hope that frameshifting-triggered gene circuits could, with further research, provide a way to selectively target cancer cells.
Written for you by our author Sanjukta Mondal, edited by Sadie Harley, and fact-checked and reviewed by Robert Egan—this article is the result of careful human work. We rely on readers like you to keep independent science journalism alive. If this reporting matters to you, please consider a donation (especially monthly). You'll get an ad-free account as a thank-you.
Publication details
Qiuyi Wang et al., Cancer-selective gene circuits via intrinsic ribosomal frameshifting, Nature (2026). DOI: 10.1038/s41586-026-11200-4
Journal information: Nature
Key medical concepts
Clinical categories
OncologyClinical genetics Who's behind this story?
Sanjukta Mondal
Master's in Chemistry. Freelance science journalist and communicator. Published in Chemistry World, BioSpace, and The Hindu. Full profile →
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
© 2026 Science X Network
Citation: Scientists turn protein-making errors in cancer cells into a targeted kill switch (2026, November 9) retrieved 9 November 2026 from https://medicalxpress.com/news/2026-11-scientists-protein-errors-cancer-cells.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.